2025 United States Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report
Description
The 2025 United States Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cancer Immunotherapy Drug Discovery Outsourcing Market in the United States include Covance, Inc., Molecular Imaging, Inc., STC Biologics, and Personalis, Inc. These firms are recognized for their advanced capabilities in cancer immunotherapy drug development and outsourcing services, leveraging technologies like AI, next-generation sequencing, and high-throughput screening to accelerate discovery and preclinical testing. Covance, a well-established CRO, offers broad drug development solutions, while Molecular Imaging focuses on innovative imaging technologies critical for target validation. STC Biologics and Personalis specialize in antibody discovery and immune profiling, respectively, key areas in immunotherapy research.
North America, led by the United States, dominates this market due to its robust healthcare infrastructure, significant R&D investments by pharmaceutical companies, and the presence of skilled medical and scientific experts. The widespread adoption of outsourcing strategies by biotech startups and large pharmaceutical firms optimizes costs and speeds development timelines. Growth drivers include increasing cancer incidence, innovations in immunotherapy modalities such as monoclonal antibodies, cancer vaccines, and adoptive T-cell therapies, and the use of advanced technologies. Additionally, governmental and private-sector initiatives further propel outsourcing demand, enabling access to cutting-edge expertise and facilities essential for cancer drug discovery.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cancer Immunotherapy Drug Discovery Outsourcing Market in the United States include Covance, Inc., Molecular Imaging, Inc., STC Biologics, and Personalis, Inc. These firms are recognized for their advanced capabilities in cancer immunotherapy drug development and outsourcing services, leveraging technologies like AI, next-generation sequencing, and high-throughput screening to accelerate discovery and preclinical testing. Covance, a well-established CRO, offers broad drug development solutions, while Molecular Imaging focuses on innovative imaging technologies critical for target validation. STC Biologics and Personalis specialize in antibody discovery and immune profiling, respectively, key areas in immunotherapy research.
North America, led by the United States, dominates this market due to its robust healthcare infrastructure, significant R&D investments by pharmaceutical companies, and the presence of skilled medical and scientific experts. The widespread adoption of outsourcing strategies by biotech startups and large pharmaceutical firms optimizes costs and speeds development timelines. Growth drivers include increasing cancer incidence, innovations in immunotherapy modalities such as monoclonal antibodies, cancer vaccines, and adoptive T-cell therapies, and the use of advanced technologies. Additionally, governmental and private-sector initiatives further propel outsourcing demand, enabling access to cutting-edge expertise and facilities essential for cancer drug discovery.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
